Trenton

Researchers are evaluating the effects of macupatide and eloralintide, alone or combined, on weight loss in adults who are overweight or have obesity along with type 2 diabetes. This Phase 2 study aims to understand how these treatments might help reduce body weight in this population. The study is designed as a parallel-group, double-blind, placebo-controlled trial to ensure unbiased results. Participants will receive either macupatide, eloralintide, both drugs together, or matching placebos. All treatments are administered by subcutaneous injection. The study treatment period lasts approximately 48 weeks, during which the effects of the drugs on weight and diabetes control will be assessed. During the study, participants will be monitored for changes in body weight from the start of the study to week 32 as the primary outcome. Researchers will also evaluate safety and other health measures throughout the nearly year-long participation. The study includes regular assessments to track the effects of treatment and to ensure participant health and safety.

Researchers are evaluating the safety and effectiveness of new treatment combinations for participants with metastatic colorectal cancer (mCRC). This Phase II global study uses a master protocol with substudies focused on participants who have mismatch-repair-proficient (pMMR) or microsatellite stable (MSS) mCRC without liver metastases and who have not previously received systemic treatment for advanced disease. Participants will be randomly assigned to one of two treatment groups: one receiving Volrustomig combined with FOLFIRI (a regimen of irinotecan, fluorouracil, and leucovorin) plus bevacizumab, and the other receiving FOLFIRI plus bevacizumab only. All medications will be given as intravenous infusions. This modular study takes place across multiple centers worldwide. During the approximately three-year participation, researchers will measure progression-free survival and monitor adverse events. Participants will undergo regular evaluations including tumor assessments by RECIST 1.1 criteria and organ function tests. Safety and treatment effects will be closely observed throughout the study period to understand the impact of these new treatment combinations.

Researchers are evaluating the safety and effectiveness of apixaban compared with aspirin in patients who recently had an intracerebral hemorrhage (ICH) and also have atrial fibrillation (AF). The study aims to find out if apixaban is better than aspirin in preventing any type of stroke or death from any cause. It also looks at whether apixaban leads to better functional recovery measured by the modified Rankin Scale. This is a phase III, randomized, double-blinded trial enrolling 700 patients over 3.5 years. Participants will be randomly assigned to receive either apixaban, an oral blood thinner that inhibits Factor Xa, or aspirin, an oral antiplatelet medication. The study lasts from 12 months up to 36 months of follow-up after enrollment. Treatments are given orally, and patients will be monitored throughout the study period. Recruitment and coordination occur through NIH/NINDS StrokeNet sites. During the study, participants will undergo assessments including brain imaging (CT or MRI) to confirm diagnosis, functional outcome measurements using the modified Rankin Scale, and monitoring for any strokes or death. Safety will be closely observed, and patients will provide informed consent before joining. The primary outcome measured is stroke or death up to 3 years, and secondary outcomes include functional status changes. Participants are followed regularly to track these outcomes and overall health status.

This research study focuses on individuals, including both adults and children, diagnosed with Chronic Granulomatous Disease (CGD). The study aims to understand how common certain antibodies against adenovirus and inflammatory proteins called cytokines are in people with CGD by measuring their levels in the blood. Blood samples will be collected from participants to measure the amount of adenovirus-specific antibodies and inflammatory cytokines circulating in their bodies. This is an observational study, meaning participants will not receive any treatments as part of the research; instead, their blood markers will be analyzed to learn more about their immune response. Participants will provide blood samples during the study, and the researchers will analyze these samples for total adenoviral-specific antibody levels and adenoviral-specific neutralizing antibody levels. The study also involves measuring inflammatory cytokines. The results will help characterize the prevalence of these markers in people with CGD. Participants or their guardians must provide informed consent and be able to follow study procedures.